The Only Sure Test for a Scarred Liver Used to Be a Needle

For decades, one definitive way existed to tell how badly a fatty liver is damaged: a needle biopsy that removes a small piece of it.

A biopsy works, but it is invasive — a lot to ask when the disease, metabolic dysfunction-associated steatotic liver disease (MASLD), affects up to one in three adults and seven in 10 people with obesity or type 2 diabetes.

Its severe form, MASH, adds active inflammation to the fat and scarring — and with the first licensed MASH drug treatments now entering practice, doctors need ways to diagnose and monitor patients without a needle.

Two studies published on October 29, 2026 — in The Lancet and Nature Medicine — just delivered the clearest answer yet.

More Than 1,800 Patients, Every Test Judged Against Biopsy

Both studies come from LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis), a programme of 53 international partners built to validate non-invasive liver tests.

The main LITMUS Study, in The Lancet, assessed blood tests and ultrasound-based liver stiffness in more than 1,500 patients — the largest international study of its kind. The companion Imaging Study, in Nature Medicine, examined advanced MRI and elastography in 357 patients.

Together, they assessed dozens of biomarkers, each compared against biopsy read by expert pathologists.

For Serious Scarring, the New Tests Are Genuinely Good

For advanced liver fibrosis (scarring) and cirrhosis, three approaches delivered the highest diagnostic accuracy: the SOMAScan proteomic panel, MR elastography (MRE), and FibroScan-based elastography, including the Agile 3+ score. In the imaging study, MRE scored an AUC of 0.91 for cirrhosis (1.0 would be perfect).

The ELF and ADAPT blood tests also cleared the studies' predefined thresholds for detecting cirrhosis, and a simple, inexpensive blood test — gamma-GT — outperformed the widely used FIB-4 score as a first-line tool.

The Honest Limits: Inflammation Is Still Hard to Catch

Here is what the studies do not show. Detecting active liver inflammation — the feature that makes MASH dangerous — remains much harder than measuring scarring. For "at-risk MASH" — the group most clinical trials target — only the SOMAScan panel met the predefined accuracy threshold. The best blood test for MASH in the imaging study, NIS2+, reached an AUC of 0.83 but did not significantly clear the minimum acceptable bar.

Because regulators still require at-risk MASH confirmation for late-stage trials, biopsy remains necessary there for now — and the pathway below still needs further validation.

A Simpler Pathway: Cheap Blood Test First, Scans Later

The findings support a staged approach: use gamma-GT as an initial screening test, follow with ELF or FibroScan where further assessment is needed, and reserve advanced imaging for specialist care.

LITMUS coordinator Professor Quentin Anstee of Newcastle University calls it "the most complete picture yet of which diagnostic tests work for liver disease," adding that for advanced scarring and cirrhosis, "we now have tools good enough to use with real confidence."

The Twikup Take

Fatty liver disease is extraordinarily common and mostly silent, and biopsy has slowed diagnosis and drug trials for years. LITMUS does not eliminate the needle — inflammation still hides from most tests — but for the scarring that matters most, blood tests and scans are now validated at hard-to-argue-with scale. The roadmap away from routine biopsy starts with a cheap blood test.

Image: AI-generated illustration.

Sources